Stem Cell and Exosome Therapy for Eczema

Eczema can wear you down, especially when itching disrupts sleep or flares keep returning. If your current routine is not giving you the comfort you want, it is reasonable to ask what else might help. Stem cells, exosomes, and supportive therapies are being explored because they may influence inflammation, skin-barrier function, and recovery in different ways.

You do not have to wait for every question to be answered before having a useful conversation about your options. The key is to understand what was studied, how it relates to the treatment being offered, and what matters to you. In a 2025 randomized trial of 114 adults, 23.7% of people who received mesenchymal stem cells (MSCs) achieved at least 75% improvement in eczema severity by week 16, compared with 7.3% who received placebo. That is an encouraging result to discuss with a clinician, while recognizing that any one person's response may differ.

Why Explore Regenerative Support for Eczema?

Eczema, also called atopic dermatitis, involves more than a rash. Inflammation can drive redness and itching, while a weakened skin barrier makes it harder to hold on to moisture and keep irritants out. Scratching can then make the skin feel even more sensitive.

Different approaches aim to support different parts of that cycle:

• Stem cells are living cells that respond to their environment and release signals involved in immune activity and tissue repair.

• Exosomes are tiny cell-derived packages that carry biological messages without administering living cells.

• Supportive wellness therapies may focus on comfort, recovery, and overall wellbeing alongside your skin-care plan.

The aim is not to choose an impressive-sounding treatment name. It is to understand how a particular option might fit your symptoms, goals, and existing care.

How Stem Cells and Exosomes May Help

Some immune signals involved in eczema, including IL-4 and IL-13, contribute to inflammation; IL-31 is associated with itch. Researchers are interested in whether signals released by MSCs or carried by exosomes can help influence that activity. They are also studying possible effects on the skin cells involved in barrier function, which matters when skin feels dry, reactive, or easily irritated.

That gives patients a practical way to think about these therapies: Could an approach help support a calmer skin environment, better moisture retention, or less disruptive itching? The biology is promising, but products and individual responses vary. It is worth discussing the particular preparation being offered rather than assuming all stem cells or exosomes work alike.

For more on the signaling involved, see immune modulation with stem cells.

Why the Cell Source and In-House Biotech Lab Matter

Two treatments can both be called "stem cell therapy" yet start with different cells, undergo different preparation, and be given in different ways. Those details matter when you are deciding how closely a study matches your options.

The randomized eczema trial studied adipose-derived MSCs, meaning cells from fat tissue. Longevity Medical Institute offers physician-supervised therapy using ethically sourced MSC and MUSE stem cells and offers exosomes independently or alongside other regenerative therapies. Its stem cell therapy information describes cell sources that include Wharton's jelly, placenta, adipose tissue, endometrium, and dental pulp. These sources should not be treated as interchangeable with the specific preparation used in the eczema trial. MUSE cells are also distinct, so ask what evidence is relevant to the option proposed for you.

What an on-site biotechnology lab adds

Longevity Medical Institute has an on-site stem cell biotechnology laboratory with separate federal COFEPRIS licensure for an ISO-certified laboratory. Its laboratory and treatment information describes assessments such as cell count, viability, sterility, traceability, and cell identity. These details help make the conversation more specific: What is the source? How was it prepared and checked? What will actually be administered?

Lab testing cannot tell you in advance exactly how your eczema will respond. It can, however, help you ask informed questions about the product rather than relying on a broad label. For more background, see exosomes versus stem cells. A review of cell and exosome research across immune-mediated diseases offers wider context, though findings in other conditions do not necessarily predict eczema outcomes.

What Have People Experienced in Eczema Studies?

The research is useful because it tells us what happened with particular preparations in particular groups of people. You can use it as a starting point for questions, not as an all-or-nothing verdict on your choices.

Stem cells: improvement in a controlled study

In the 2025 phase 2 trial, 114 adults received intravenous infusions of their own adipose-derived MSCs or placebo. By week 16, 23.7% of the MSC group reached EASI-75, a measure of at least 75% improvement in eczema severity, compared with 7.3% of the placebo group. For someone living with frequent flares, that difference is a meaningful reason to ask about the approach.

Smaller studies of bone marrow MSCs add to the conversation, although they involve different cells and study designs. The overview of mesenchymal stem cell research provides more background.

Exosomes: changes in comfort and skin-barrier measures

In a 2025 study of 20 adults with facial atopic dermatitis, participants used a topical adipose-derived MSC exosome formulation twice daily for six weeks. Researchers reported improvements in hydration, moisture loss from the skin, itch, and visible severity, with no adverse events reported during the study. Those outcomes speak directly to concerns many people with eczema have every day.

The study did not include a comparison group, so it cannot show how much improvement came from the exosome formulation rather than other factors. It still offers useful observations to bring into an informed discussion, especially if skin-barrier comfort is one of your priorities.

The takeaway: There are encouraging human findings for specific MSC and exosome approaches. Ask how closely a proposed product, route, and goal match what was studied, and decide with your clinician how you would assess whether it is helping you.

Build on the Care That Already Supports Your Skin

Being curious about regenerative options does not mean giving up treatments that help. Moisturizers and barrier care, prescription topical treatments, phototherapy, and, when appropriate, biologics or oral JAK inhibitors can remain part of a personalized eczema plan. A clinician can help you decide how to combine or adjust care around your goals.

If you would like to rely less on topical steroids, say so. That can lead to a constructive conversation about skin location, flare frequency, and other options rather than a choice between doing everything or stopping everything. Longevity Medical Institute's dermatology and skin health services can be part of that conversation.

Longevity Recharge Station and HBOT: Supportive Options to Discuss

Eczema can affect more than your skin. Rest, stress, and feeling worn down by symptoms can matter just as much when you think about quality of life. Supportive therapies can give you another way to discuss those priorities, even if their purpose differs from a prescription eczema treatment.

The Longevity Recharge Station combines 10-wavelength photobiomodulation light therapy, molecular hydrogen inhalation, vagus nerve stimulation, and micro-impact plate therapy. These modalities are offered as part of a broader recovery and wellness experience. For someone whose eczema affects rest or day-to-day comfort, the conversation might focus on relaxation, recovery, and how feeling better supported fits into their overall skin-care routine. The station combines several modalities, so it is important not to treat evidence for one as proof of an eczema benefit from the full experience.

Hyperbaric oxygen therapy (HBOT) involves breathing oxygen in a pressurized chamber. Its potential to support oxygen delivery and tissue-repair processes is one reason people ask about it as part of a broader recovery plan. A published report on HBOT and atopic dermatitis described improvements that included less itching in the people studied. That is an encouraging point to discuss if itch or recovery is a priority, while recognizing that it does not predict what any individual will experience.

Neither service needs to be presented as a replacement for your regular eczema care. Ask what benefit you are hoping for, how that benefit would be noticed, and whether a service fits your health history. HBOT also calls for an individual safety assessment before treatment. If a flare appears infected or is rapidly worsening, seek prompt clinical advice.

Questions to Help You Make an Informed Choice

You know how eczema affects your life. A useful consultation connects that experience with the specifics of any proposed therapy. Consider asking:

1. What would this option aim to support for me? Less itch, more comfortable skin, better rest, or another goal?

2. What exactly would I receive? Ask whether it is MSCs, MUSE cells, exosomes, HBOT, or a Recharge Station session, and how it would be delivered.

3. Where does it come from? If cells or exosomes are proposed, ask about source, donor screening when relevant, preparation, and lab assessments.

4. How does the available evidence relate to this option? Did a study use the same type of product and route for people with eczema?

5. How will we assess my experience? Itch, sleep, flare days, comfort, skin appearance, and medication use can all be useful measures.

6. What should I know about safety and follow-up? Discuss current treatments, infections, pregnancy, other health conditions, and what to do if symptoms change.

Studies of one preparation cannot answer every question about another, so the product-specific discussion matters. This patient guide to stem cell therapy safety can help you prepare.

Make room for hope and a practical plan

You can be hopeful, curious, and discerning at the same time. Bring your eczema history, what has and has not helped, and the changes you most want to feel in everyday life. A physician-led conversation can then explore which regenerative or supportive options, if any, make sense alongside your existing care.

Longevity Medical Institute offers ethically sourced MSC and MUSE stem cell therapy, exosome therapy, an on-site biotechnology lab, the Longevity Recharge Station, and HBOT within physician-supervised programs. Its lab capabilities can make questions about sourcing and preparation more concrete, while your priorities help guide the wider discussion.

If you are considering stem cell and exosome therapy for eczema, visit Longevity Medical Institute to discuss an individualized assessment and which options may fit your goals.

Medically reviewed by the physician-led clinical team at Longevity Medical Institute.

This information is for educational purposes only and is not medical advice. It does not replace an evaluation by a qualified healthcare professional. For personalized guidance, please schedule a consultation.

Article Information

Author
Dr. Kirk Sanford, DC. Founder & CEO, Longevity Medical Institute. Dr. Sanford focuses on patient education in regenerative and longevity medicine, translating complex therapies into clear, practical guidance for patients.

Medical Review
Dr. Félix Porras, MD. Medical Director, Longevity Medical Institute. Dr. Porras provides clinical oversight and medical review to help ensure accuracy, safety context, and alignment with current standards of care.

Last Reviewed: October 25, 2026

Disclaimer
This information is for educational purposes only and is not medical advice. It does not replace an evaluation by a qualified healthcare professional. For personalized guidance, please schedule a consultation.